Caisse DE Depot ET Placement DU Quebec raised its position in shares of Zoetis Inc (NYSE:ZTS) by 332.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,937 shares of the company’s stock after buying an additional 32,247 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Zoetis were worth $3,573,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Dupont Capital Management Corp lifted its position in shares of Zoetis by 2.5% during the second quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock valued at $2,088,000 after buying an additional 601 shares during the last quarter. Dorsey Wright & Associates increased its holdings in shares of Zoetis by 7.9% during the second quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock valued at $714,000 after acquiring an additional 617 shares in the last quarter. Wrapmanager Inc. increased its holdings in shares of Zoetis by 7.9% during the second quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock valued at $782,000 after acquiring an additional 672 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Zoetis by 16.0% during the first quarter. Jones Financial Companies Lllp now owns 5,337 shares of the company’s stock valued at $446,000 after acquiring an additional 738 shares in the last quarter. Finally, CENTRAL TRUST Co increased its holdings in shares of Zoetis by 3.1% during the second quarter. CENTRAL TRUST Co now owns 25,747 shares of the company’s stock valued at $2,193,000 after acquiring an additional 783 shares in the last quarter. 89.79% of the stock is owned by institutional investors and hedge funds.

In related news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $84.76, for a total value of $169,520.00. Following the transaction, the insider now owns 22,023 shares in the company, valued at approximately $1,866,669.48. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Juan Ramon Alaix sold 135,000 shares of the stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $91.55, for a total transaction of $12,359,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 213,467 shares of company stock worth $19,488,185. 0.35% of the stock is owned by corporate insiders.

Shares of NYSE:ZTS opened at $88.24 on Wednesday. Zoetis Inc has a twelve month low of $62.79 and a twelve month high of $93.67. The company has a debt-to-equity ratio of 2.50, a quick ratio of 2.92 and a current ratio of 4.38. The company has a market capitalization of $43.09 billion, a P/E ratio of 36.77, a price-to-earnings-growth ratio of 1.84 and a beta of 1.02.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.38 billion. During the same quarter in the prior year, the company earned $0.53 EPS. Zoetis’s quarterly revenue was up 11.5% on a year-over-year basis. analysts forecast that Zoetis Inc will post 3.07 earnings per share for the current year.

Several equities analysts have recently issued reports on the stock. BMO Capital Markets restated a “hold” rating and set a $82.00 price objective on shares of Zoetis in a report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Friday, July 27th. Stifel Nicolaus upped their price objective on shares of Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Bank of America upped their price objective on shares of Zoetis from $97.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 30th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $101.00 price objective on the stock in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $91.73.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Using the New Google Finance Tool

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.